Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?

Por Peters, Godefridus J., Giovannetti, Elisa, Honeywell, Richard J., Ciccolini, Joseph
Publicado no Br J Clin Pharmacol (2019)

Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance

Por de Klerk, Daniel J., Honeywell, Richard J., Jansen, Gerrit, Peters, Godefridus J.
Publicado no Cancers (Basel) (2018)

Coexisting Molecular Determinants of Acquired Oxaliplatin Resistance in Human Colorectal and Ovarian Cancer Cell Lines

Por Noordhuis, Paul, Laan, Adrianus C., van de Born, Kasper, Honeywell, Richard J., Peters, Godefridus J.
Publicado no Int J Mol Sci (2019)

Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine

Por Adema, Auke D, Floor, Karijn, Smid, Kees, Honeywell, Richard J, Scheffer, George L, Jansen, Gerrit, Peters, Godefridus J
Publicado no Springerplus (2014)

Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126

Por Adema, Auke D., Smid, Kees, Losekoot, Nienke, Honeywell, Richard J., Verheul, Henk M., Myhren, Finn, Sandvold, Marit L., Peters, Godefridus J.
Publicado em 2011

Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth

Por Rovithi, Maria, de Haas, Richard R., Honeywell, Richard J., Poel, Dennis, Peters, Godefridus J., Griffioen, Arjan W., Verheul, Henk M. W.
Publicado no J Exp Clin Cancer Res (2016)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance

Por Honeywell, Richard J., Kathmann, Ietje, Giovannetti, Elisa, Tibaldi, Carmelo, Smit, Egbert F., Rovithi, Maria N., Verheul, Henk M.W., Peters, Godefridus J.
Publicado no Cancers (Basel) (2020)

Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A (DZNeP) with gemcitabine in pancreatic cancer cells

Por Avan, Amir, Crea, Francesco, Paolicchi, Elisa, Funel, Niccola, Galvani, Elena, Marquez, Victor E, Honeywell, Richard J., Danesi, Romano, Peters, Godefridus J., Giovannetti, Elisa
Publicado em 2012

Cellular pharmacology of multi- and duplex drugsconsisting of ethynylcytidine and 5-fluoro-2′-deoxyuridine

Por Bijnsdorp, Irene V., Schwendener, Reto A., Schott, Herbert, Fichtner, Iduna, Smid, Kees, Laan, Adrie C., Schott, Sarah, Losekoot, Nienke, Honeywell, Richard J., Peters, Godefridus J.
Publicado em 2009

Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors

Por Rovithi, Maria, Gerritse, Sophie L., Honeywell, Richard J., ten Tije, Albert J., Ruijter, Rita, Peters, Godefridus J., Voortman, Jens, Labots, Mariette, Verheul, Henk M.W.
Publicado no J Clin Oncol (2019)

RX-3117 (Fluorocyclopentenyl-Cytosine)-Mediated Down-Regulation of DNA Methyltransferase 1 Leads to Protein Expression of Tumor-Suppressor Genes and Increased Functionality of the...

Por Sarkisjan, Dzjemma, Julsing, Joris R., El Hassouni, Btissame, Honeywell, Richard J., Kathmann, Ietje, Matherly, Larry H., Lee, Young B., Kim, Deog J., Peters, Godefridus J.
Publicado no Int J Mol Sci (2020)

DNA-Bound Platinum Is the Major Determinant of Cisplatin Sensitivity in Head and Neck Squamous Carcinoma Cells

Por Martens-de Kemp, Sanne R., Dalm, Simone U., Wijnolts, Fiona M. J., Brink, Arjen, Honeywell, Richard J., Peters, Godefridus J., Braakhuis, Boudewijn J. M., Brakenhoff, Ruud H.
Publicado em 2013

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib

Por Gotink, Kristy J., Rovithi, Maria, de Haas, Richard R., Honeywell, Richard J., Dekker, Henk, Poel, Dennis, Azijli, Kaamar, Peters, Godefridus J., Broxterman, Henk J., Verheul, Henk M. W.
Publicado no Cell Oncol (Dordr) (2015)

Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasc...

Por Gotink, Kristy J., Broxterman, Henk J., Honeywell, Richard J., Dekker, Henk, de Haas, Richard R., Miles, Kiersten M., Adelaiye, Remi, Griffioen, Arjan W., Peters, Godefridus J., Pili, Roberto, Verheul, Henk M.W.
Publicado no Oncoscience (2014)

A rapid homogeneous immunoassay to quantify gemcitabine in plasma for therapeutic drug monitoring (TDM)

Por Kozo, Daniel, Ross, Matt W., Jarrah, Justin, Barrett, Michael, Harney, Rebecca L., Courtney, Jodi B., Baburina, Irina, Holleran, Julianne L., Beumer, Jan H., Peters, Godefridus J., Honeywell, Richard J., Salamone, Salvatore J.
Publicado no Ther Drug Monit (2017)

Adherence and Patients' Experiences with the Use of Capecitabine in Daily Practice

Por Timmers, Lonneke, Boons, Christel C. L. M., Mangnus, Dirk, Van de Ven, Peter M., Van den Berg, Pieter H., Beeker, Aart, Swart, Eleonora L., Honeywell, Richard J., Peters, Godefridus J., Boven, Epie, Hugtenburg, Jacqueline G.
Publicado no Front Pharmacol (2016)

Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function

Por Van Der Steen, Nele, Keller, Kaylee, Dekker, Henk, Porcelli, Letizia, Honeywell, Richard J., Van Meerloo, Johan, Musters, René J. P., Kathmann, Ietje, Frampton, Adam E., Liu, Daniel S. K., Ruijtenbeek, Rob, Rolfo, Christian, Pauwels, Patrick, Giovannetti, Elisa, Peters, Godefridus J.
Publicado no J Cell Physiol (2020)

Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance

Por Gotink, Kristy J., Broxterman, Henk J., Labots, Mariette, de Haas, Richard R., Dekker, Henk, Honeywell, Richard J., Rudek, Michelle A., Beerepoot, Laurens V., Musters, René J., Jansen, Gerrit, Griffioen, Arjan W., Assaraf, Yehuda G., Pili, Roberto, Peters, Godefridus J., Verheul, Henk M.W.
Publicado no Clin Cancer Res (2011)

Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome

Por Labots, Mariette, Pham, Thang V., Honeywell, Richard J., Knol, Jaco C., Beekhof, Robin, de Goeij-de Haas, Richard, Dekker, Henk, Neerincx, Maarten, Piersma, Sander R., van der Mijn, Johannes C., van der Peet, Donald L., Meijerink, Martijn R., Peters, Godefridus J., van Grieken, Nicole C.T., Jiménez, Connie R., Verheul, Henk M.W.
Publicado no Cancers (Basel) (2020)